{"analyses":[{"ciLowerLimit":"0.469","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.061","estimateComment":"HR:unadjusted stratified Cox proportional hazard regression with stratification(low-blast AML,IPSS-R risk groups=very high,high,or intermediate for HRMDS/CMML),treatment as factor.HR\\<1:better prevention of EFS in combination arm than azacitidine arm.","groupDescription":"Event-Free Survival (EFS)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.092","pValueComment":"P-value comparing EFS between treatment groups was based on the unstratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.706","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.96","upperLimit":"20.50","value":"17.6"},{"groupId":"OG001","lowerLimit":"17.41","upperLimit":"28.02","value":"21.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"EFS is defined as the time from the date of randomization to the date of the occurrence of an event. An event is defined as death or transformation to AML for HR MDS/CMML participants, whichever occurs first, or defined as death for low-blast AML participants. HR MDS/CMML participants without documented EFS event will be censored at the date of the last response assessment. HR MDS/CMML participants with no response assessment and no death will be censored at the date of randomization. Low-blast AML participants without documentation of death will be censored at the date the participant was last known to be alive. HR MDS/CMML participants who received alternative antineoplastic therapy before death or transformation to AML will be censored at the date of last adequate assessment prior to starting alternate antineoplastic therapy. The Kaplan-Meier estimate was used for the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"ITT Population was defined as all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From date of randomization until transformation to AML, or death due to any cause (up to approximately 5 years)","title":"Event-Free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"months"}